Citizens JMP raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $81 from $75 and keeps an Outperform rating on the shares. Rhythm Pharmaceuticals continues its impressive commercial execution, with key Phase 3 data in hypothalamic obesity coming in 2Q25, the analyst tells investors in a research note. The firm continues to like Imcivree’s commercial dynamics, with management projecting growth at a steady pace in approved indications as the company works to expand into new indications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $81 from $80 at Canaccord
- Rhythm Pharmaceuticals: Strong Buy Rating Backed by IMCIVREE’s Growth and Promising Pipeline Developments
- Rhythm Pharmaceuticals: Hold Rating Amid Strong Imcivree Sales and Upcoming HO Trial Data
- Rhythm Pharmaceuticals Reports Strong 2024 Growth and Strategic Advances
- Rhythm Pharmaceuticals: Strong Commercial Execution and Promising Pipeline Drive Buy Rating